Zelasudil (RXC007) is a selective inhibitor of Rho-associated coiled-coil-containing kinase 2 (ROCK2). It has been found to have the antifibrotic effect.

Zelasudil (RXC007) is a selective inhibitor of Rho-associated coiled-coil-containing kinase 2 (ROCK2). It has been found to have the antifibrotic effect.

Zelasudil (RXC007) is a selective inhibitor of Rho-associated coiled-coil-containing kinase 2 (ROCK2). It has been found to have the antifibrotic effect.

Zelasudil (RXC007) is a selective inhibitor of Rho-associated coiled-coil-containing kinase 2 (ROCK2). It has been found to have the antifibrotic effect.

BAY-593 is an in vivo probe and small molecule inhibitor of geranylgeranyltransferase-I (GGTase-I), blocking oncogenic YAP1/TAZ. It exhibits potent anti-tumor activity and inhibits cancer cell proliferation in vitro.

BAY-593 is an in vivo probe and small molecule inhibitor of geranylgeranyltransferase-I (GGTase-I), blocking oncogenic YAP1/TAZ. It exhibits potent anti-tumor activity and inhibits cancer cell proliferation in vitro.

BAY-593 is an in vivo probe and small molecule inhibitor of geranylgeranyltransferase-I (GGTase-I), blocking oncogenic YAP1/TAZ. It exhibits potent anti-tumor activity and inhibits cancer cell proliferation in vitro.

BAY-593 is an in vivo probe and small molecule inhibitor of geranylgeranyltransferase-I (GGTase-I), blocking oncogenic YAP1/TAZ. It exhibits potent anti-tumor activity and inhibits cancer cell proliferation in vitro.

HC-7366, is a First-in-Human modulator of General controlled nonderepressible 2 (GCN2) that activates GCN2. It demonstrates anti-metastatic efficacy, reducing lung metastases and exhibits anti-tumor activity.

HC-7366, is a First-in-Human modulator of General controlled nonderepressible 2 (GCN2) that activates GCN2. It demonstrates anti-metastatic efficacy, reducing lung metastases and exhibits anti-tumor activity.